Catalyst appoints new CMO
This article was originally published in Scrip
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare diseases, has appointed Dr Gary Ingenito chief medical officer. Dr Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr Ingenito will report to Dr Steven Miller, Catalyst's chief operating officer and chief scientific officer. Current chief medical officer at Catalyst, Dr Charles Gorodetzky, will continue to serve as a consultant to the company.